The epidermis has >1,000 Langerhans cells per cm2, and there are established mouse lines in which a fluorescent protein marks these cells. The monitoring of fluorescently labelled proteins and agents can be combined with autofluorescent properties of the microenvironment to provide a comprehensive snapshot of in vivo cell biology. Intravital or in vivo microscopy (IVM) has emerged as a powerful technique for the anatomical and functional mapping of cell biology in live mice from the subcellular level to whole-body approaches. The introduction of fluorescent proteins into mice by genetic engineering has opened exciting opportunities to track live cell biology and molecular dynamics in vivo. Combined IVM of fluorescent proteins with other fluorescently tagged probes, such as antibodies, drugs, or nanoparticles, while also exploring the inherent or autofluorescent properties of endogenous compounds, such as extracellular matrix or metabolites, can provide a comprehensive biological insight into live animals with an improved fidelity compared with cell and tissue-culture models. Furthermore, the use of multiphoton microscopy with pulsed infrared lasers provides key advantages for IVM as this can significantly extend the imaging depths owing to the reduced absorption and scattering at longer excitation wavelengths, while providing strong optical sectioning. Although Prof. Kabashima did not explore any single hypothesis in his talk, he demonstrated how his team uses models of ichthyosis vulgaris, among others, to video neutrophil activity and keratinocyte dynamics to gain exciting insights into the intricate regulation of live cell biology at the microscale level.
Figure: Psoriasiform dermatitis with a subcorneal pustule. Data on file.Haematoxylin and eosin stain, original magnification 4X
- Kabashima K. O020 SPIN 2019, 25-27 April, Paris, France.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis? Next Article
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients »
« Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis? Next Article
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients »
Table of Contents: SPIN 2019
Featured articles
Letter from the Editor
Aetiology: Triggers and Risk Factors
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy